CFMS - Conformis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.3500
+0.0400 (+1.73%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.3100
Open2.2900
Bid2.0200 x 3100
Ask2.4600 x 1400
Day's Range2.2800 - 2.3600
52 Week Range0.3580 - 4.8300
Volume807,879
Avg. Volume1,084,729
Market Cap161.395M
Beta (3Y Monthly)2.17
PE Ratio (TTM)N/A
EPS (TTM)-0.5150
Earnings DateOct 30, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.13
Trade prices are not sourced from all markets
  • GlobeNewswire

    Conformis to Host Third Quarter 2019 Financial Results Webcast on October 30, 2019

    BILLERICA, Mass., Oct. 15, 2019 -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will host a webcast on Wednesday, October 30, 2019, at 4:30 p.m. Eastern Time to.

  • Globenewswire Test

    Conformis Announces Departure of Paul Weiner, CFO

    BILLERICA, Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell patient-specific joint replacement implants designed to fit each patient’s unique anatomy, announced today that Paul Weiner, Chief Financial Officer, has notified the Company that he will be departing the Company on October 18, 2019 to become the Chief Financial Officer at a privately-owned business in Fremont, CA. As a result, the Company’s Board of Directors has begun a search to appoint a successor to Mr. Weiner, with a further announcement to be made in due course. Mr. Weiner has agreed to work with Conformis as an advisor to help achieve a smooth transition.Mark Augusti, Chief Executive Officer, said: “Paul has been our CFO since 2014 and was instrumental in taking Conformis public. He has been a valued member of the management team and has made a huge contribution to the success of the business. On behalf of the Company and the Board, I would like to thank him for his work and contributions over many years.”Mr. Weiner said: “I have been privileged to work with an outstanding team during my tenure at Conformis. I thank the Board and the leadership team for their support and enjoyed my interactions with all the employees and business partners. I leave the Company both financially and operationally strong at an extremely exciting time with the recently announced development, license, and distribution agreements with Stryker. I am confident that Conformis will continue to deliver value for shareholders and customers alike.”About Conformis, Inc.Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient’s unique anatomy. Conformis offers a broad line of customized knee and hip implants and customized pre-sterilized, single-use instruments delivered to the hospital. In clinical studies, Conformis iTotal CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover customized implants and customized patient-specific instrumentation for all major joints.For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at ir.conformis.com.Cautionary Statement Regarding Forward-Looking StatementsStatements in this press release about our future expectations, plans and prospects, including statements about the anticipated timing of our search for a new Chief Financial Officer, development, license, and distribution agreements with Stryker, our financial position and results, total revenue, product revenue, gross margin, operations, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. We may not actually achieve the forecasts disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual financial results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to our estimates and expectations regarding our revenue, gross margin, expenses, revenue growth and other results of operations, and the other risks and uncertainties described in the “Risk Factors” sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.CONTACT: Investor contact ir@conformis.com (781) 374-5598

  • Company News For Oct 2, 2019
    Zacks

    Company News For Oct 2, 2019

    Companies In The News Are: ROAN, CFMS, NERV, REED

  • GlobeNewswire

    Conformis and Stryker Execute Development, License and Distribution Agreements

    Conformis, Inc. (CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell patient-specific joint replacement implants designed to fit each patient’s unique anatomy, announced today that it has entered into definitive agreements to sell and license to Stryker Corporation, one of the world’s leading medical technology companies, certain assets relating to Conformis’ patient-specific instrumentation (PSI) technology, and to develop, manufacture, and supply PSI for use in connection with Stryker’s knee implant offerings.

  • Do Insiders Own Shares In Conformis, Inc. (NASDAQ:CFMS)?
    Simply Wall St.

    Do Insiders Own Shares In Conformis, Inc. (NASDAQ:CFMS)?

    A look at the shareholders of Conformis, Inc. (NASDAQ:CFMS) can tell us which group is most powerful. Generally...

  • ACCESSWIRE

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Conformis, Inc. - CFMS

    NEW YORK, NY / ACCESSWIRE / August 7, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Conformis, Inc. (“Conformis” or the “Company”) (CFMS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Conformis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • PR Newswire

    Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Conformis, Inc. (CFMS)

    NEW YORK , Aug. 6, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Conformis, Inc. ("Conformis"  or ...

  • Thomson Reuters StreetEvents

    Edited Transcript of CFMS earnings conference call or presentation 31-Jul-19 8:30pm GMT

    Q2 2019 Conformis Inc Earnings Call

  • ConforMIS (CFMS) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    ConforMIS (CFMS) Reports Q2 Loss, Tops Revenue Estimates

    ConforMIS (CFMS) delivered earnings and revenue surprises of 0.00% and 1.20%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Conformis Reports Second Quarter 2019 Financial Results and Updates Product Revenue Expectations

    BILLERICA, Mass., July 31, 2019 -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop,.

  • ConforMIS (CFMS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks

    ConforMIS (CFMS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Conformis Establishes Alliance to Focus on ASC Joint Replacement

    BILLERICA, Mass., July 15, 2019 -- Conformis, Inc. (NASDAQ: CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop,.

  • GlobeNewswire

    Conformis to Host Second Quarter 2019 Financial Results Webcast on July 31, 2019

    BILLERICA, Mass., July 15, 2019 -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will host a webcast on Wednesday, July 31, 2019, at 4:30 p.m. Eastern Time to discuss.

  • Hottest Wall Street Stories of First Half
    Zacks

    Hottest Wall Street Stories of First Half

    We discuss some of the events that dominated the headlines in the first half and influenced the market.

  • GlobeNewswire

    Conformis Secures Up to $30 Million in Debt Financing and $3 Million in Equity Financing from Innovatus Life Sciences and East West Bank

    Conformis, Inc. (CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell patient specific joint replacement implants designed to fit each patient's unique anatomy, announced today that the Company has secured up to $30 million in debt financing from Innovatus Capital Partners, LLC (“Innovatus”) and East West Bank and $3 million in equity financing from Innovatus. This financing is part of Conformis’ comprehensive financing strategy to optimize its capital structure and to provide the funding for driving its commercialization. Conformis will use the proceeds from the debt financing to payoff the $15 million term loan from Oxford Finance LLC and currently expects that the remainder will be used for general corporate purposes, including but not limited to funding its working capital needs.

  • 3 Stocks Under $5 Hitting New Highs
    Investopedia

    3 Stocks Under $5 Hitting New Highs

    These low-priced stocks are attracting healthy buying interest despite sub-par small-cap performance so far in 2019.

  • Introducing Conformis (NASDAQ:CFMS), The Stock That Zoomed 170% In The Last Year
    Simply Wall St.

    Introducing Conformis (NASDAQ:CFMS), The Stock That Zoomed 170% In The Last Year

    Unless you borrow money to invest, the potential losses are limited. But when you pick a company that is really...

  • Thomson Reuters StreetEvents

    Edited Transcript of CFMS earnings conference call or presentation 1-May-19 8:30pm GMT

    Q1 2019 Conformis Inc Earnings Call

  • ConforMIS (CFMS) Reports Q1 Loss, Tops Revenue Estimates
    Zacks

    ConforMIS (CFMS) Reports Q1 Loss, Tops Revenue Estimates

    ConforMIS (CFMS) delivered earnings and revenue surprises of 0.00% and 2.64%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press

    ConforMIS: 1Q Earnings Snapshot

    On a per-share basis, the Billerica, Massachusetts-based company said it had a loss of 12 cents. The results met Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire

    Conformis Reports First Quarter 2019 Financial Results

    BILLERICA, Mass., May 01, 2019 -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop,.

  • Can iTotal PS Revenues Drive ConforMIS' (CFMS) Q1 Earnings?
    Zacks

    Can iTotal PS Revenues Drive ConforMIS' (CFMS) Q1 Earnings?

    ConforMIS (CFMS) expects to register solid revenue growth on robust performance by its product lines as well as steady royalties.